#None #Philadelphia #CEO Appointment #Minaris #Orla Cloak

Minaris Advanced Therapies Welcomes Dr. Orla Cloak as CEO

Minaris Advanced Therapies, a leading global contract development and manufacturing organization (CDMO), has officially appointed Dr. Orla Cloak as its Chief Executive Officer. This announcement marks a significant moment for the company as it focuses on expanding its influence in the field of cell and gene therapies.

Dr. Cloak is recognized as an accomplished leader in the pharmaceutical and biotechnology industries, boasting extensive experience spanning over 20 years. Before joining Minaris, Cloak held various senior management roles at Lonza, a prominent player in the life sciences sector, for 17 years. Her most recent position was Senior Vice President, where she led the Lonza Biosciences division.

A graduate of the University College Dublin with a Bachelor of Science, Dr. Cloak also holds a Ph.D. in Microbiology from the University of Ulster. Her diverse background and proven track record in driving innovation, operational excellence, and sustainable business growth are expected to propel Minaris's strategic vision forward.

Iain Baird, Chairman of Minaris Advanced Therapies, expressed enthusiasm about Dr. Cloak's appointment, emphasizing her leadership skills are poised to support the company's mission of helping clients successfully market their innovative therapies. He stated, “On behalf of the board, I am delighted to welcome Orla to Minaris Advanced Therapies. Her leadership will be crucial in helping us achieve our goals.”

In response to her new role, Dr. Cloak noted, “I am honored to join Minaris Advanced Therapies at such a pivotal time. I look forward to collaborating with the talented team here to build upon the company's strong foundation and drive the next phase of growth.”

Minaris Advanced Therapies is dedicated exclusively to supporting the development of cell and gene therapies. Headquartered in Philadelphia, Pennsylvania, the company operates a robust infrastructure spanning over 650,000 square feet across the United States, Europe, and Asia. With over 7,500 GMP (Good Manufacturing Practice) batches manufactured and released, Minaris has established a global network to support therapy developers during early development, clinical trials, and commercial manufacturing.

Furthermore, as part of Altaris, an investment firm focused exclusively on building and acquiring healthcare companies, Minaris stands at the forefront of innovative healthcare solutions. Altaris has invested in over 50 companies across various healthcare subsectors since its establishment in 2003, aiming to create value for the healthcare system and deliver attractive financial returns.

The future looks promising for Minaris Advanced Therapies under Dr. Orla Cloak's leadership, as the company continues to enhance its capabilities and expand its role in the thriving sector of advanced therapies. With her extensive background and commitment, both the board and the teams at Minaris are optimistic about what lies ahead.

For further inquiries, media representatives can contact Tishesa Aaron at [email protected]

For more information about Minaris Advanced Therapies, visit www.minaris.com.

About Minaris Advanced Therapies

Minaris Advanced Therapies specializes in providing contract development and manufacturing services tailored exclusively for cell and gene therapies. Its dedication to excellence is reflected in its ability to produce high-quality therapeutic solutions for clients worldwide.

About Altaris

Altaris is a healthcare-focused investment firm dedicated to acquiring and building companies in the healthcare sector. Established in 2003, Altaris has cultivated a portfolio that spans various healthcare segments, consistently aiming to generate value and deliver financial returns for its investors.